Regulus Therapeutics, through its microMarkers division, has entered a new collaboration with Biogen Idec aimed at identifying microRNAs as biomarkers for multiple sclerosis (MS). The new research will focus on profiling whole blood samples from a cohort of MS patients who have been treated with Biogen’s MS therapy to identify potential microRNA signatures. Regulus will receive $2 million upfront and is eligible for future milestones related to the identification of potential microRNA signatures...